Rockwell Medical, Inc. (NASDAQ:RMTI) has received a consensus rating of “Hold” from the six analysts that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell rating, one has given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $9.33.

A number of research analysts recently issued reports on RMTI shares. BidaskClub lowered Rockwell Medical from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. ValuEngine lowered Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Ifs Securities started coverage on Rockwell Medical in a report on Monday, August 14th. They issued a “strong-buy” rating and a $11.00 target price for the company.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Rockwell Medical by 4.6% during the second quarter. Vanguard Group Inc. now owns 2,080,843 shares of the company’s stock worth $16,501,000 after purchasing an additional 90,786 shares in the last quarter. State Street Corp increased its position in shares of Rockwell Medical by 7.4% during the second quarter. State Street Corp now owns 903,142 shares of the company’s stock worth $7,160,000 after purchasing an additional 62,094 shares in the last quarter. Northern Trust Corp increased its position in shares of Rockwell Medical by 4.8% during the second quarter. Northern Trust Corp now owns 618,045 shares of the company’s stock worth $4,901,000 after purchasing an additional 28,482 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Rockwell Medical by 9.7% during the first quarter. Geode Capital Management LLC now owns 371,700 shares of the company’s stock worth $2,326,000 after purchasing an additional 32,964 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in shares of Rockwell Medical by 1.1% during the second quarter. TIAA CREF Investment Management LLC now owns 132,131 shares of the company’s stock worth $1,048,000 after purchasing an additional 1,401 shares in the last quarter. Institutional investors and hedge funds own 21.37% of the company’s stock.

Shares of Rockwell Medical (NASDAQ RMTI) opened at 6.28 on Friday. The firm has a 50 day moving average price of $6.67 and a 200 day moving average price of $6.97. The stock’s market capitalization is $324.93 million. Rockwell Medical has a one year low of $3.55 and a one year high of $8.98.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.04. The firm had revenue of $13.24 million for the quarter, compared to analysts’ expectations of $13.05 million. Rockwell Medical had a negative return on equity of 42.22% and a negative net margin of 39.68%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.11) earnings per share. Analysts predict that Rockwell Medical will post ($0.44) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Rockwell Medical, Inc. (RMTI) Receives Consensus Rating of “Hold” from Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/08/rockwell-medical-inc-rmti-receives-consensus-rating-of-hold-from-analysts.html.

Rockwell Medical Company Profile

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.